SOLICITATION NOTICE
B -- Evaluation of the mutational spectrum of gallbladder cancer cases with pancreaticobiliary maljunction compared to those with gallstones
- Notice Date
- 9/5/2017
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP72688-73
- Point of Contact
- Ronette P. Collins, Phone: 2402765745, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ronette.collins@nih.gov, jolomi.omatete@nih.gov
(ronette.collins@nih.gov, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB), plans to procure on a sole source basis services to conduct tissue processing and assays including laser capture microdissection, DNA extraction, and targeted exome sequencing on samples that they have collected from their study "Gallbladder Cholecystopathy Project" for Emory University, 1599 Clifton Rd., Atlanta, GA 30322. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 541990 and the business size standard is $15.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. Pancreatobiliary maljunction (PBM) is the anomalous union of pancreatic duct with common bile duct several centimeters away from the gallbladder rather than at the duodenum. This abnormal union can be associated with other anatomic variations of the biliary system including choledochal cysts and has been associated with gallbladder cancer (GBC) to the extent that PBM diagnosis is considered an indication for prophylactic cholecystectomy. One consequence of PBM is reflux of pancreatic juices to the biliary system including up to the gallbladder. Some studies have found amylase, a pancreatic enzyme, in the gallbladder bile fluid from patients with PBM, confirming this reflux. Pathologists from Emory and Japan/Korea have found that the gallbladders from PBM patients show a distinctive type of mucosal hyperplasia, further supporting a distinct etiology compared to gallstone-associated GBC. The NCI have recently completed whole exome sequencing on approximately 60 gallbladder cancer cases from areas where gallstones are the primary etiologic factor. Thus, molecular analysis of PBM-associated GBCs offers a unique opportunity to compare the molecular differences between PBM-associated GBCs and gallstone-associated GBCs. This comparison may identify novel molecular pathways that inform our understanding of etiology. Emory has access to a series of approximately 30 PBM-associated GBCs. Carcinoma cells in the gallbladder are often widely dispersed and paucicellular (low cell density). Thus, the NCI propose to use laser capture microdissection (LCM) of the tumor to enhance findings and estimate that 20-25 of the cases will have sufficient material for molecular analysis. The NCI then plans to conduct targeted exome sequencing towards a panel of 562 cancer-related genes using hybrid capture technologies. Analysis of gallstone-associated GBCs is in process and will also inform the genes included on this panel. By focusing on comparing the mutational spectra with prior results, the NCI can sequence to greater depth, reducing false-positives and false-negatives in a cost-effective manner. Emory's proprietorship of the samples that will be used to compare against the NCI study samples qualifies them as the only agency that can satisfy requirements for this study. Contract requirements The contractor shall perform the following tasks on 25 samples: Task 1: Laser capture microdissection Task 2: Immunohistochemistry Task 3: Fluorescent in situ hybridization Task 4: DNA extraction, targeted exome sequencing, computational analyses, data management and delivery This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11:00 AM EST, on September 11, 2017. All responses and questions must be in writing and faxed 240-276-5399 or emailed to Ronette Collins, Contract Specialist via electronic mail at ronette.collins@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02PC72688-73 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP72688-73/listing.html)
- Record
- SN04661400-W 20170907/170905231730-d52bca408a929ef50ef4c970d94b723d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |